---
title: "ANKE BIO signed a strategic cooperation framework agreement with Weisheng Pharmaceutical"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248385249.md"
description: "ANKE BIO announced on July 14th that it has signed a strategic cooperation framework agreement with Weisheng Pharmaceutical. According to the agreement, ANKE BIO will be responsible for the market promotion of Longpei Growth Hormone products in specific regions within China through exclusive promotion. In addition, both parties agreed to conduct broader and deeper cooperation discussions on other target products, covering various aspects such as localized production and commercialization cooperation"
datetime: "2025-07-14T09:33:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248385249.md)
  - [en](https://longbridge.com/en/news/248385249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248385249.md)
generator: "portal-rs"
---

# ANKE BIO signed a strategic cooperation framework agreement with Weisheng Pharmaceutical

On July 14th, ANKE BIO announced that it has signed a strategic cooperation framework agreement with Weisheng Pharmaceutical. According to the agreement, ANKE BIO will be responsible for the market promotion of Longpei Growth Promoting Factor products in specific regions within China through exclusive promotion. In addition, both parties agreed to conduct broader and deeper cooperation discussions on other target products, covering multiple aspects such as localized production and commercialization promotion cooperation

### Related Stocks

- [300009.CN](https://longbridge.com/en/quote/300009.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [Implantica: FDA approval and 66% sales growth set the stage for a major U.S. launch and global expansion](https://longbridge.com/en/news/296629680.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**